Welcome to our dedicated page for Xbiotech SEC filings (Ticker: XBIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The XBiotech Inc (NASDAQ: XBIT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. XBiotech is a British Columbia, Canada corporation with headquarters in Austin, Texas, and it uses its SEC reports to communicate material information about governance, executive compensation, shareholder votes and other corporate matters related to its True Human™ antibody business.
Through current reports on Form 8‑K, XBiotech has disclosed events such as the appointment of new members to its board of directors and their roles on the Audit and Compensation Committees, as well as the terms of an executive employment agreement that outlines compensation and severance arrangements for a senior leader. Other 8‑K filings describe material agreements and provide context on how the company structures leadership transitions and board oversight.
The company’s definitive proxy statement on Schedule 14A details items presented at its annual meeting of shareholders, including the election of directors, ratification of its independent registered public accounting firm, advisory votes on executive compensation and approval of an equity incentive plan. The proxy materials also explain voting procedures, record dates and how shareholders can participate in the virtual annual meeting format.
On Stock Titan, these filings are available alongside AI‑powered summaries that highlight key points from lengthy documents such as proxy statements and 8‑K exhibits. Users can review vote results, committee composition, and compensation structures, and can track how XBiotech’s governance and corporate policies evolve over time. Real‑time updates from EDGAR, combined with AI explanations, help readers quickly understand the implications of new filings without having to parse every page of the underlying documents.
Thomas Martin Kuendig, a director of XBiotech Inc. (XBIT), filed an initial Form 3 disclosing beneficial ownership of 300,000 shares of the issuer's common stock. The filing reports 200,000 shares held directly and two indirect holdings of 50,000 shares each attributed to his daughters, Stephanie Kuendig and Michelle Kuendig. The event requiring the statement is dated 08/29/2025 and the form is signed on 09/29/2025. No derivative securities are reported on this form.
Form 3 filed for XBiotech Inc. (XBIT) by Troy Tevi David, indicating his status as a director of the issuer. The filing states the date of the event requiring the statement as 08/29/2025 and discloses that no securities are beneficially owned by the reporting person at the time of filing. The form is signed and dated 09/29/2025.
Craig Evan Rademaker filed an initial Form 3 reporting beneficial ownership in XBiotech Inc. (XBIT). The filing shows 104,237 shares held indirectly by the Rademaker 2020 Trust and 66,748 shares held indirectly by his spouse, for a combined disclosed position of 170,985 shares. The form identifies Mr. Rademaker as a director and was signed on 09/16/2025.
XBiotech Inc. held its annual stockholder meeting on August 29, 2025, where all management-backed proposals were approved. Stockholders elected five directors: John Simard, Thomas Kündig, Craig Rademaker, Tevi D. Troy and David Soffer, each receiving over 12.3 million votes in favor or abstentions only.
Stockholders ratified Whitley Penn LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025, with 15,206,712 votes for and 413,673 against. They also approved, on an advisory basis, executive compensation and approved the Company’s 2025 Equity Incentive Plan, each with more than 11.9 million votes in favor.
XBiotech Inc. reported narrower losses in the quarter ended June 30, 2025 with a three-month net loss of $1.8 million and a six-month net loss of $12.6 million, down from $13.0 million and $23.0 million a year earlier. Revenue remained nil and operating expenses fell as clinical trial activity decreased and certain executive compensation timing shifted; research and development totaled $5.3 million for the quarter and $17.0 million year-to-date. The company held $152.9 million in cash and cash equivalents at June 30, 2025, down from $172.7 million at December 31, 2024, and used $12.7 million of cash in operations during the six months ended June 30, 2025.
The company repaid and terminated a $10.0 million related-party convertible loan on January 31, 2025, extinguishing conversion rights. Total assets were $178.7 million and shareholders' equity was $173.1 million as of June 30, 2025. XBiotech states its cash is sufficient to achieve several major inflection points and to fund operations for at least 12 months from the report date.
XBiotech announced two significant appointments to its Board of Directors on June 24, 2025. The company has appointed Dr. Thomas Kündig and Craig Rademaker as new board members, with immediate effect until the 2025 Annual General Meeting.
Key appointments and roles:
- Dr. Kündig, Director of Dermatology at University Hospital Zurich, joins the Compensation Committee. He brings expertise in immunodermatology and pioneering work in intralymphatic immunotherapy (ILIT)
- Mr. Rademaker, a financial industry veteran with 25+ years experience, joins the Audit Committee. He currently leads a Private Equity firm managing assets over $5 billion
The updated committee structure now includes:
- Audit Committee: Jan-Paul Waldin, Dr. Peter Libby, and Craig Rademaker
- Compensation Committee: Jan-Paul Waldin, Dr. Peter Libby, and Dr. Thomas Kündig